Biopharmaceutical company RemeGen Co. Ltd. (9995.HK) (SHA:688331) announced on Tuesday the first patient enrollment in the US for its global phase III clinical trial of telitacicept for generalized myasthenia gravis (gMG).
This milestone advances the global clinical development of telitacicept, offering new hope to gMG patients worldwide. Telitacicept has previously received orphan drug and fast track status from the FDA and breakthrough therapy designation from China's NMPA for myasthenia gravis.
The phase III trial is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating telitacicept's efficacy and safety in treating gMG. It aims to recruit 180 patients across multiple countries and regions. Myasthenia gravis is a rare autoimmune disease impairing neuromuscular junctions, affecting eye movement, swallowing, speech, general movement, and respiratory function. Current treatments include cholinesterase inhibitors, glucocorticoids, and immunosuppressants, but unmet medical needs persist due to efficacy, tolerability and contraindication issues.
Telitacicept is a dual targeting fusion protein attacking BLyS and APRIL, reducing pathogenic antibody production by targeting B cells and plasma cells. Preliminary studies indicate telitacicept's potential to continuously and effectively improve the clinical status of gMG patients.
Merck acquires Curon's CN201 for USD700m upfront
Precision BioSciences partner TG Therapeutics receives IND clearance for azer-cel
RemeGen begins US phase III trial of telitacicept for myasthenia gravis
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
BioSenic expands US patent portfolio for ATO use in sepsis treatment
Q32 Bio added to Russell 3000 Index
Sareum reports positive data from SDC-1801 Phase 1 trial
BenevolentAI and AstraZeneca collaboration leads to novel target for lupus